Longer time in blood pressure target range improves cardiovascular outcomes among patients with Type 2 diabetes: A Secondary Analysis of a Randomized Clinical Trial.

  • KangYu Chen
  • , Zhenqiang Wu
  • , Rui Shi
  • , Qi Wang
  • , Xiaodan Yuan
  • , Guohong Wu
  • , Guoshuai Shi
  • , Chao Li
  • , Tao Chen

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

To examine the prognostic value of time in target range (TIR) with adverse outcomes and validate it with common blood pressure (BP) metrics among patients with Type 2 diabetes mellitus. We performed a post hoc analysis of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial. TIR for each subject was calculated using linear interpolation and an SBP target range of 110 to 130mmHg. Cox models were used to assess the association of TIR and other BP metrics with the rate of clinical outcomes. A higher TIR (61.9-100.0%) was associated with a 46% reduction in major adverse cardiovascular events (MACE) (hazard ratio [HR]:0.54; 95% CI: 0.43, 0.67) compared with TIR 0-22.9%. Results were similar for stroke (0.19; 0.10, 0.36), myocardial infarction (0.67; 0.51, 0.89), heart failure (0.47; 0.33, 0.66), cardiovascular death (0.63; 0.42, 0.93) and all-cause mortality (0.70; 0.54, 0.91). Further analyses suggested a curvilinear association of TIR with MACE, and this association was independent with baseline, final SBP, mean SBP, or visit-to-visit SBP variability. Longer TIR is associated with lower cardiovascular risk and may add value as an outcome measure for hypertension control studies among patients with diabetes..

Original languageEnglish
Article number110600
Pages (from-to)e110600
JournalDiabetes Research and Clinical Practice
Volume198
DOIs
Publication statusPublished - 27 Feb 2023

Keywords

  • Blood pressure
  • Cardiovascular disease
  • Diabetes mellitus
  • Hypertension

Fingerprint

Dive into the research topics of 'Longer time in blood pressure target range improves cardiovascular outcomes among patients with Type 2 diabetes: A Secondary Analysis of a Randomized Clinical Trial.'. Together they form a unique fingerprint.

Cite this